Table 1 Characteristics of the included studies on prevalence of headache among patients with epilepsy
From: The epidemiology of headaches among patients with epilepsy: a systematic review and meta-analysis
First author, date | Country | Sample size | Study design | Data collection tool | Prevalence (%) | Prevalence of any headache (%) | Prevalence (%) | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Male | Female | MA | MOA | TTH | IIH | PIH | ||||||
Erin K, 2017 [34] | USA | 160 | Cross-sectional | Self-report | NA | NA | 40.00 | NA | Â | Â | Â | Â |
Singla et al., 2019 [35] | India | 123 | Cohort | Self-report | NA | NA | 47.10 | 21.10 | Â | 26.00 | Â | Â |
Sayena J et al., 2015 [36] | Iran | 150 | Cross-sectional | MSQ | NA | NA | 32.60 | 15.30 | 17.30 | Â | Â | Â |
Ashjazadeh N, 2015 [37] | Iran | 100 | Cross-sectional | ICHD-II | 48 | 52 | 54.00 | 15.00 | Â | 39.00 | 42.53 | 31.48 |
Fattahzadeh AG et al., 2017 [38] | Iran | 900 | Cross-sectional | HIS | NA | NA | 85.20 | 27.90 | Â | 48.20 | Â | Â |
Ito M et al., 2004 [26] | Japan | 364 | Cross-sectional | ICHD-III | NA | NA | 40.40 | 26.00 | Â | Â | 50.00 | 40.40 |
Inn-Chi L., 2018 [47] | Taiwan | 476 | Cross-sectional | ICHD-III | NA | NA | 9.70 | 9.70 | Â | Â | Â | Â |
Mainieri et al., 2015 [39] | Italy | 388 | Cross-sectional | ICHD-II | NA | NA | 53.90 | 26.30 | Â | 19.10 | 48.50 | 19.10 |
Zhang et al., 2018 [37] | China | 339 | Cross-sectional | ICHD-III | 17 | 29 | 23.00 | 23.00 | Â | Â | Â | Â |
Gökhan Ö et al., 2010 [41] | Turkey | 86 | Cohort | Self-report | NA | NA | 47.60 | 13.90 | 12.80 | 16.30 |  |  |
Mameniškiene R et al., 2016 [42] | Lithuania | 289 | Cross-sectional | HALT | 42 | 62 | 83.20 | 31.70 |  | 39.00 | 77.90 |  |
Wang et al., 2014 [25] | China | 1109 | Cross-sectional | ICHD-II | 57 | 64 | 60.10 | 60.20 | Â | 30.30 | 11.70 | 34.10 |
Slavica V. et al., 2012 [43] | Montenegro | 259 | Cross-sectional | ICDH II | 20 | 85 | 48.00 | 15.44 | Â | Â | Â | 28.00 |
Shamim R..,2018 [44] | Bangladesh | 376 | Cross-sectional | NA | NA | NA | 80.60 | NA | Â | Â | Â | 80.60 |
Kwan P et al., 2008 [38] | China | 227 | Cohort | HIT-6 | 68 | NA | 22.00 | 4.80 | 3.10 | 7.00 | 19.80 | Â |
Yosria AHA. et al., 2017 [41] | Egypt | 118 | Case control | ICHD-III | 31 | 69 | 24.60 | 79.30 | Â | Â | Â | Â |
Sayed MA et al, 2019 [42] | Egypt | 100 | Cross-sectional | ICHD-III | 27 | 73 | 78.00 | 70.60 | Â | 25.58 | 50.00 | 66.50 |